Navigation Links
New 'Reaxys' Solution Improves Workflow Quality and Efficiency for Chemists
Date:1/26/2009

FRANKFURT, Germany, January 26 /PRNewswire-FirstCall/ --

- Elsevier's New Web-Based Solution Combines Content From the Trusted CrossFire Databases in a Highly Intuitive and Easy to use Interface With New Features and Functionality

Elsevier, the leading publisher of scientific, medical and technical products and services, today introduced Reaxys, a new workflow solution for synthetic chemists. Reaxys is based on data from Elsevier's industry leading chemistry databases (CrossFire Beilstein, CrossFire Gmelin and Patent Chemistry Database) now merged together to provide harmonized content, additional functionalities and a redesigned interface to help improve R&D efficiency. Reaxys also contains new unique features including a synthesis planner and advanced results handling to help scientists gather relevant information more efficiently.

"Scientists, both in academia and industry, are under increasing pressure to deliver more and better results in a shorter time and make research decisions faster," said Mark van Mierle, managing director for Elsevier Information Systems. "Reaxys now gives them a tool to quickly create an overview of the of synthesis design options available for their work, research and quickly identify and select the most appropriate. By integrating chemical reaction and substance data from trusted sources with a synthesis design process, customers can accelerate early phase discovery."

    Features include:

    - Workflow and decision making support for synthesis design and
      planning, e.g. by comparing alternative synthesis routes and selecting
      the most relevant paths;
    - Quick access to key data by displaying results in a unique
      tabulated overview of the most important information;
    - Convenient and flexible output of data in most common formats.

Reaxys has been developed with input and advice from development partners from corporate and academic research institutions around the world. In addition, the web interface has been designed by experts in human-computer interaction. The look and feel has been streamlined to make searching easier and provide a clear visualization of the results.

The result is a solution that goes beyond retrieving data. Search results reflect how chemists think and work, helping their workflow move seamlessly from initial search, recognition of possible starting materials and their properties and through planning a strategy for the synthesis of a new compound to proposing a detailed synthetic route. Most compounds in Reaxys can be identified by their CAS Registry Numbers(R).

Migrating from Crossfire to Reaxys

Reaxys is available today and existing CrossFire customers may use Reaxys in parallel for an interim period. Elsevier offers full training and helpdesk support for new customers as well as guidance for the migration from CrossFire to the new platform. For the time being all CrossFire products as well as the Commander interface will be fully supported.

Select customers have been evaluating Reaxys throughout its development and have provided positive feedback. Elsevier will continue to engage with the chemistry community in future product development. For more information, visit http://www.info.reaxys.com.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (http://www.sciencedirect.com/), MD Consult (http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/), bibliographic databases, and online reference works.

Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Reaxys(TM) and CrossFire Beilstein are owned and protected by Elsevier Properties SA and used under license.

More about the addition of CAS Registry Numbers(R) can be found in a recent agreement between CAS (Chemical Abstract Service) and Elsevier: http://www.info.reaxys.com/press_room.

    Tom Reller (For U.S.)
    Director, Corp. Relations
    +1-212-462-1912
    T.Reller@Elsevier.com

    Emma Potter (Europe/Asia)
    Kaizo Public Relations
    +44-(0)20-3043-4191
    EPotter@Kaizo.net



'/>"/>
SOURCE Elsevier
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sentillion Introduces Affordable Next Generation Healthcare Single Sign-On Solution Called expreSSO(TM)
2. Ken Sperling to Lead CIGNA HealthCare Retiree Solutions Unit
3. Office-Based Medical Treatment and Internet Resources Are Potential Solution to Rising Painkiller Misuse Among Teens, Young Adults
4. Methadone and systematic follow-up: the best solution for managing chronic pain
5. Frances Decker Named Mid-Atlantic Region Sales Executive for AllOne Health Management Solutions
6. Mirixa Debuts New Clinical Technology Solutions for Enhancing Patient Care
7. LodgeNet Deploys Customized Kid Friendly Solution With Childrens Hospital of Pittsburgh of UPMC
8. Amcat Partners With Gryphon to Provide Comprehensive and Guaranteed Do Not Call (DNC) Compliance Solution for Outbound Contact Activities
9. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
10. Century City Doctors Hospital Goes Live With Global Care Quests ICIS Solution
11. AT&T Offers Network Industry-First RFID Solution for Health Care Organizations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... New York (PRWEB) , ... May 23, 2017 ... ... NextGen LifeLabs, a leading equipment provider in the modern ART laboratory, to provide ... Institute in Ft. Lauderdale, Florida. , NextGen LifeLabs, a MedTech Group Purchasing ...
(Date:5/23/2017)... MA (PRWEB) , ... May 23, 2017 , ... Orbita’s ... on Tuesday, May 23, 2017 in San Francisco. Titled Connected Health and IoT: ... Connected Home Event hosted by Parks Associates, a market research and consulting firm ...
(Date:5/23/2017)... San Francisco, California (PRWEB) , ... May 23, 2017 , ... ... released results of its new survey in an infographic on the current state of ... 900 U.S. respondents, familiar with anxiety, was conducted in April 2017 and benchmarked general ...
(Date:5/22/2017)... Kisco, NY (PRWEB) , ... May 22, 2017 , ... ... are urged to receive relaxing sedation dentistry in Mt. Kisco, NY from Advanced Endodontics ... be administered for a variety of treatments. One or more sedation methods may be ...
(Date:5/22/2017)... ... May 22, 2017 , ... An inventor from Columbia, S.C., ... pen. "My wife’s hand was damaged in a firework accident, so she couldn’t grip ... with manual problems." , He then designed and created a prototype for the HELPEN ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... PHILADELPHIA , May 15, 2017 Enterin Inc., ... and developing novel compounds to treat Parkinson,s disease ... The study is a Phase 1/2a randomized, controlled, multicenter study ... sites. It will enroll 50 patients over a 9-to-12-month period. ... doses in 10 patients with PD. Participating sites include ...
(Date:5/10/2017)...  The Corporate Whistleblower Center says, "We are ... clinics to call us anytime at 866-714-6466 if they ... in a substantial scheme to overbill Medicare. We ... employee of a medical equipment company if their ... medical practice groups with extra generous incentives to use, ...
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals Inc. ... a clinical-stage pharmaceutical company focused on the development ... the Canadian Intellectual Property Office has granted Oramed ... Administration of Exenatide". The patent covers Oramed,s invention ... GLP-1 is an incretin hormone that stimulates ...
Breaking Medicine Technology: